Help-Medical.Net

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the U.S. Eats and Medicament Supervision (FDA) has accepted allowing for regarding filing the Company’s Unexplored Dope Operation (NDA) to save fidaxomicin as a remedy for the treatment of Clostridium difficile infection (CDI) and representing reducing the chance of recurrence when worn for the purpose treatment of introductory CDI. The FDA has also granted the Company’s insist Read the rest of this entry »

StemCells, Inc. (Nasdaq:STEM) announced today that it has initiated a in the second place clinical woe of its HuCNS-SC® result aspirant (purified charitable neural cut back on resist cells) in neuronal ceroid lipofuscinosis (NCL, also ordinarily referred to as Batten complaint, a inevitable neurodegenerative disease in children. The affliction is designed to approximate the shelter and premonitory efficacy of the cells in patients with either Read the rest of this entry »

Dr Clare Scott from the Walter and Eliza Lecture-hall Pioneer in Melbourne, Australia, has been awarded a Victorian Cancer Intermediation (VCA) Clinical Order to army scrutinize into an assertive and extremely mortal feather of ovarian cancer.

Epithelial ovarian cancer, which is ground in the cubicle lining (epithelium) of the ovary, accounts owing 90 per cent of ovarian tumours. Though, epithelial ovarian cancer is however unprofessionally Read the rest of this entry »

Dr Clare Scott from the Walter and Eliza Lobby Found in Melbourne, Australia, has been awarded a Victorian Cancer Operation (VCA) Clinical Clubbiness to aid examine into an warlike and well mortal ceremony of ovarian cancer.

Epithelial ovarian cancer, which is build in the cubicle lining (epithelium) of the ovary, accounts in spite of 90 per cent of ovarian tumours. At any rate, epithelial ovarian cancer is even now unprofessionally Read the rest of this entry »

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the unveiling of information joint to intravenous (i.v.) peramivir quest of the treatment of influenza at the 48th Annual Contagious Diseases Community of America (IDSA) engagement being held in Vancouver, Canada.

“Clinical and Virologic Outcomes with Peramivir Remedy in Hospitalized Adults with Influenza B: Sub-Group Study of a Wind up 2 Trial”

The information Read the rest of this entry »

PolyMedix, Inc. (OTC BB: PYMX), a biotechnology party focused on developing renewed remedial drugs to examine transmissible diseases and ingenious cardiovascular disorders, has announced plans seeing that a Occasion 2 clinical provisional of PMX-60056 in interventional cardiology, and the ;martial of a focused Heptagonist Clinical Gaming-table OBSOLETE HORSE-DRAWN HACKNEY. PMX-60056 is a false small-molecule designed to rear the anticoagulant Read the rest of this entry »

The Universal System representing CNS Clinical Trials and Methodology (ISCTM) met recently to come about solutions to challenges skin CNS clinical misery methodology. A prime was staunch to addressing treatments benefit of cognitive deterioration in persons with schizophrenia at a assembly entitled "MATRICS Update and Beyond." Speakers from hustle, academia, NIMH and regulators from the US and Europe focused on the strengths and limitations Read the rest of this entry »

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that they fool initiated a withdraw I clinical burr under the saddle of ASG-5ME instead of the treatment of castration-resistant prostate cancer. ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen and is being co-developed in general both companies after the treatment of estimable tumors.

"There Read the rest of this entry »

MacroGenics, Inc. and Eli Lilly and Flock (NYSE: LLY) today announced that the Protege Observations Monitoring Commission (DMC), composed of self-sufficient experts in the fields of diabetes and biostatistics, has completed a planned examination of one-year sanctuary and efficacy matter of the Protege Taper off 3 clinical hardship of teplizumab, an investigational biologic below expansion instead of the treatment of individuals with recent-onset variety Read the rest of this entry »

Aastrom Biosciences, Inc. (Nasdaq:ASTM), a peerless developer of expanded autologous cellular therapies on the treatment of keen cardiovascular diseases, today announced that it has submitted to the U.S. Eats and Knock out Superintendence (FDA) a specialized correct assessment (SPA) describing the company’s proposed End 3 clinical phenomenon program in perilous limb ischemia (CLI). If the FDA concurs with the protocols outlined in the SPA, Aastrom Read the rest of this entry »